These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8937134)

  • 1. A lipid lowering drug (bezafibrate) has a favorable effect on liver enzymes (Al-P and gamma-GTP).
    Fukuo Y; Kitami T; Nomoto T; Terashi A
    Nihon Ika Daigaku Zasshi; 1996 Oct; 63(5):424-30. PubMed ID: 8937134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bezafibrate for the treatment of primary sclerosing cholangitis.
    Mizuno S; Hirano K; Tada M; Yamamoto K; Yashima Y; Yagioka H; Kawakubo K; Ito Y; Kogure H; Sasaki T; Arizumi T; Togawa O; Matsubara S; Nakai Y; Sasahira N; Tsujino T; Isayama H; Kawabe T; Omata M; Koike K
    J Gastroenterol; 2010 Jul; 45(7):758-62. PubMed ID: 20127368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels.
    Kita R; Takamatsu S; Kimura T; Kokuryu H; Osaki Y; Tomono N
    J Gastroenterol; 2006 Jul; 41(7):686-92. PubMed ID: 16933007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway.
    Nakamuta M; Fujino T; Yada R; Yasutake K; Yoshimoto T; Harada N; Yada M; Higuchi N; Kato M; Kohjima M; Taketomi A; Maehara Y; Nishinakagawa T; Machida K; Matsunaga K; Nakashima M; Kotoh K; Enjoji M
    Int J Clin Pharmacol Ther; 2010 Jan; 48(1):22-8. PubMed ID: 20040336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.
    Spieker LE; Noll G; Hannak M; Lüscher TF
    J Cardiovasc Pharmacol; 2000 Mar; 35(3):361-5. PubMed ID: 10710119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
    Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined effects of probucol and benzafibrate on lipoprotein metabolism and liver cholesteryl ester transfer protein mRNA in cholesterol-fed rabbits.
    Ou J; Saku K; Jimi S; Liao YL; Ohta T; Zhang B; Arakawa K
    Jpn Circ J; 1999 Jun; 63(6):471-7. PubMed ID: 10406588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel treatment for refractory primary biliary cirrhosis?
    Miyaguchi S; Ebinuma H; Imaeda H; Nitta Y; Watanabe T; Saito H; Ishii H
    Hepatogastroenterology; 2000; 47(36):1518-21. PubMed ID: 11148991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bezafibrate for primary biliary cirrhosis.
    Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD009145. PubMed ID: 22259000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
    Farnier M; Salko T; Isaacsohn JL; Troendle AJ; Dejager S; Gonasun L
    Am J Cardiol; 2003 Oct; 92(7):794-7. PubMed ID: 14516878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia.
    Tesone PA; Gladstein J; Acuña AM
    Curr Med Res Opin; 1985; 9(9):650-7. PubMed ID: 3902379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.
    Kawashiri MA; Kobayashi J; Nohara A; Noguchi T; Tada H; Nakanishi C; Inazu A; Mabuchi H; Yamagishi M
    Clin Chim Acta; 2011 May; 412(11-12):1068-75. PubMed ID: 21354122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coagulofibrinolytic assessment of effects of bezafibrate on hypertriglyceridemia in postmenopausal women.
    Ushiroyama T; Ikeda A; Higashio S; Ueki M
    Blood Coagul Fibrinolysis; 2000 Dec; 11(8):709-14. PubMed ID: 11132648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
    Dohmen K; Tanaka H; Haruno M
    Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of bezafibrate and simvastatin on plasma lipoproteins in hypercholesterolemia resistant to hormone replacement therapy.
    Ohmichi M; Ikegami H; Kurachi H; Node K; Morishige K; Nishio Y; Adachi K; Matumoto K; Hayakawa J; Tasaka K; Azuma C; Murata Y
    Maturitas; 2001 May; 38(3):279-86. PubMed ID: 11358645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration.
    Totsuka M; Miyashita Y; Ito Y; Watanabe H; Murano T; Shirai K
    Atherosclerosis; 2000 Nov; 153(1):175-9. PubMed ID: 11058713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.
    Kawano M; Kuroda Y; Terao M; Yaginuma T; Kawakami M; Kanazawa Y
    Clin Chim Acta; 2002 Apr; 318(1-2):91-5. PubMed ID: 11880117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of the antilipemic effect of bezafibrate with that of piperazine-sultosilate (A 585). A crossed double-blind study].
    Vinazzer H
    Wien Klin Wochenschr; 1984 Dec; 96(24):889-93. PubMed ID: 6152088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.